NCT06856031Completed
the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis
A Retrospective Analysis on the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Patients With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 4 Mar 2025
Brief summary (registry, in English)
The drug retention rate of vedolizumab for ulcerative colitis decreases with time. This study analyzed the long-term drug retention rate and its influencing factors in patients with moderately to severely active ulcerative colitis treated with vedolizumab.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 152 (actual)
- First submitted
- 10 Feb 2025
- Start date
- 1 Nov 2020
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Diseases
- Ulcerative colitis
- NCT number
- NCT06856031
What you commit to
- Study type: Observational
- Participants enrolled: 152
- From 1 Nov 2020 to the primary completion date, 30 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Combination therapy with other biological agents, small molecule drugs, immunosuppressants or hormone therapy.
Other illness
- Combination of active tuberculosis, Clostridium difficile infection, cytomegalovirus infection, EBV infection, etc.
- Combined with malignant tumors or autoimmune diseases (such as dry syndrome, systemic lupus erythematosus, rheumatoid arthritis, etc.).
- Combined with serious cardiovascular and cerebrovascular diseases or liver and renal insufficiency.
- Loss of visit or clinical data ≥30% during the follow-up period.
Who the study is looking for
- Diagnosed with moderate to severe ulcerative colitis
- Receiving treatment with vedolizumab
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Affiliated Hospital of Wenzhou Medical University Coordinator of this site? Confirm its status | Wenzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.